Drug Profile
Research programme: allergy therapeutics - Precigen Inc/Stallergenes Greer plc
Latest Information Update: 10 Feb 2020
Price :
$50
*
At a glance
- Originator ActoGeniX
- Developer Precigen Inc; Stallergenes Greer plc
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 28 Dec 2018 No recent reports of development identified for preclinical development in Allergy in Belgium (PO)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Allergy in France (PO)